Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Aims to Launch GnuBio Sequencer within Two Years, Discloses Purchase Price of up to $110M

Premium

This article was originally published May 12.

NEW YORK (GenomeWeb) − Bio-Rad Laboratories plans to commercialize GnuBio's droplet-based sequencing technology within two years, the company said last week. It also disclosed that it paid $40 million in cash for GnuBio when it acquired the firm last month, and could make up to $70 million in development and sales milestone payments over the next three years.

For several years, GnuBio has been developing a hybridization-based microdroplet sequencing technology, which uses a picoinjector method developed by co-founder David Weitz at Harvard University. Last year, the company started shipping its first instruments to beta customers and said it was expecting to commercialize the platform, which focuses on targeted sequencing of dozens of genes and offers an integrated workflow, by the summer or fall of 2014.

Bio-Rad said last month that it plans to commercialize GnuBio's technology for clinical diagnostics, initially in the areas of oncology, HLA testing, and infectious diseases, and to obtain regulatory clearance for the instrument and assays from the US Food and Drug Administration. The technology, it said, complements and expands its existing droplet digital PCR technology.

During a conference call to discuss Bio-Rad's first quarter earnings last week, Chief Financial Officer Christine Tsingos said that "it will likely take a few years to bring this product to market." Over the next few quarters, Bio-Rad "will be investing heavily to bring this exciting new technology to the diagnostic market," she said, approximately $5 million for R&D per quarter, which will be booked under its clinical diagnostics unit.

Asked about a timeline for commercialization, Brad Crutchfield, president of Bio-Rad's Life Science group, said that "there is a lot of work to do" on getting the integrated cartridge technology "bulletproof" as well as to clear regulatory hurdles, which he said is "certainly something we wish to do within two years."

In bringing a new sequencing platform to market for clinical applications, Bio-Rad will compete with several players. Qiagen, for example, is working on commercializing the GeneReader, which is based on technology it obtained through the acquisition of Intelligent Bio-Systems in 2012. Last week, Qiagen said it has postponed the launch of the system, which will be part of a workflow that is aimed at clinical laboratories, to 2015.

Also, Roche teamed up with Pacific Biosciences last year to develop a sequencing system and assays for clinical diagnostics, paying the firm $35 million in cash and up to another $40 million for development milestones, but it has not provided a commercialization timeline.

In the meantime, Illumina remains the only company with an FDA-cleared next-gen sequencer on the market, the MiSeq Dx, while Thermo Fisher's Ion Torrent plans to register the PGM with the FDA this fall.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.